Sientra Inc (NASDAQ:SIEN) Shares Sold by Parametric Portfolio Associates LLC
Parametric Portfolio Associates LLC decreased its position in shares of Sientra Inc (NASDAQ:SIEN) by 22.0% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 14,062 shares of the medical instruments supplier’s stock after selling 3,957 shares during the quarter. Parametric Portfolio Associates LLC’s holdings in Sientra were worth $87,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors have also recently modified their holdings of SIEN. Bailard Inc. grew its stake in shares of Sientra by 28.9% during the 2nd quarter. Bailard Inc. now owns 25,000 shares of the medical instruments supplier’s stock worth $154,000 after purchasing an additional 5,600 shares during the period. Trexquant Investment LP acquired a new stake in shares of Sientra during the 2nd quarter worth approximately $172,000. Wells Fargo & Company MN grew its stake in shares of Sientra by 127.1% during the 2nd quarter. Wells Fargo & Company MN now owns 52,594 shares of the medical instruments supplier’s stock worth $324,000 after purchasing an additional 29,430 shares during the period. Charles Schwab Investment Management Inc. grew its stake in Sientra by 27.1% in the 2nd quarter. Charles Schwab Investment Management Inc. now owns 69,482 shares of the medical instruments supplier’s stock valued at $429,000 after acquiring an additional 14,800 shares during the period. Finally, Kornitzer Capital Management Inc. KS acquired a new stake in Sientra in the 2nd quarter valued at $462,000. 88.91% of the stock is currently owned by institutional investors and hedge funds.
Sientra stock opened at $6.43 on Monday. The company’s fifty day moving average price is $6.63 and its 200 day moving average price is $6.72. Sientra Inc has a 1 year low of $4.78 and a 1 year high of $23.32. The stock has a market capitalization of $320.39 million, a P/E ratio of -1.98 and a beta of 0.24. The company has a debt-to-equity ratio of 0.18, a quick ratio of 1.99 and a current ratio of 2.33.
SIEN has been the topic of a number of research analyst reports. Stephens set a $16.00 price target on shares of Sientra and gave the company a “buy” rating in a research note on Friday, August 9th. Canaccord Genuity set a $13.00 price target on shares of Sientra and gave the company a “buy” rating in a research note on Tuesday, September 24th. BidaskClub raised shares of Sientra from a “sell” rating to a “hold” rating in a research note on Thursday, October 10th. Craig Hallum dropped their price target on shares of Sientra from $20.00 to $14.00 and set a “buy” rating on the stock in a research note on Thursday, July 25th. Finally, ValuEngine raised shares of Sientra from a “hold” rating to a “buy” rating in a research note on Wednesday, October 2nd. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and eight have given a buy rating to the company’s stock. Sientra currently has a consensus rating of “Buy” and a consensus target price of $15.75.
Sientra Company Profile
Sientra, Inc, a medical aesthetics company, develops and sells medical aesthetics products to plastic surgeons in the United States. It operates through two segments, Breast Products and miraDry. The company offers silicone gel breast implants for use in breast augmentation and breast reconstruction procedures; breast tissue expanders; and scar management products under the Sientra, AlloX2, Dermaspan, Softspan, and BIOCORNEUM brand names.
Featured Article: Systematic Risk
Receive News & Ratings for Sientra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sientra and related companies with MarketBeat.com's FREE daily email newsletter.